My research has focused on the use of comprehensive genomic methods, next generation sequencing, and computational and predictive modeling to discover new genomic abnormalities in leukemia and other cancers, and, translating these to discoveries to improved means of cancer diagnosis, monitoring, and therapeutic intervention.

During my career, I have led several multidisciplinary, multi-institutional teams of scientists and physicians focused on: 1) discovery of genomic abnormalities and their translation to new diagnostics, predictive genomic signatures, and targeted therapeutic interventions to improve outcome in leukemia; 2) discovery of novel spectra of cancer-promoting genomic mutations and genome-wide mutational signatures reflective of environmental exposures and cancer risk behaviors in disparities cancers; and 3) development of new therapeutic strategies, including nanotherapeutics, in pre-clinical animal models and national clinical trials through the NCTN.